Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:842945.
doi: 10.1155/2012/842945. Epub 2012 Aug 2.

Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma

Roberta Martiniani  1 , Valentina Di Loreto, Chiara Di Sano, Alessandra Lombardo, Anna Marina Liberati
Affiliations

Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma

Roberta Martiniani et al. Adv Hematol. 2012.

Abstract

Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It belongs to the second generation of immunomodulatory drugs (IMiDs) and possesses pleiotropic properties. Even if lenalidomide has been shown to be active in the treatment of several hematologic malignancies, this review article is mostly focalized on its mode of action in multiple myeloma. The present paper is about the direct and indirect antitumor effects of lenalidomide on malignant plasmacells, bone marrow microenvironment, bone resorption and host's immune response. The molecular mechanisms and targets of lenalidomide remain largely unknown, but recent evidence shows cereblon (CRBN) as a possible mediator of its therapeutical effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Lenalidomide and thalidomide structure.
Figure 2
Figure 2
SDF-1α actions and its functional sequelae.
Figure 3
Figure 3
NF-kB activation and its functional biological sequelae.
Figure 4
Figure 4
Induction of IL-6 secretion by TNFα and NF-kB activation.
Figure 5
Figure 5
Signaling pathways activated by BM cytokines.
See this image and copyright information in PMC

References

    1. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Annals of the Rheumatic Diseases. 1999;58(supplement 1):I107–I113. - PMC - PubMed
    1. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. The New England Journal of Medicine. 2005;352(6):549–557. - PubMed
    1. List AF. Lenalidomide: from bench to bedside (part 1) Cancer Control. 2006;13(supplement 2-3) - PubMed
    1. List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2006;13(supplement 4–11) - PubMed
    1. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86–93. - PubMed

LinkOut - more resources